The new patent named, ‘Neurotherapeutic compositions comprising a beta-lactam compound,’ includes compounds including clavulanic acid and moxalactam as a treatment for neurological disorders like, Alzheimer’s disease, anxiety, dementia, Parkinson’s disease and depression.
The patent also covers the use and pharmaceutical formulation of those compounds.
Rexahn president Rick Soni said obtaining this European patent coverage for clavulanic acid and moxalactam broadens and strengthens their CNS-related portfolio, which includes Serdaxin, currently in Phase II clinical trials.